LeishMan recommendations for treatment of cutaneous and mucosal leishmaniasis in travelers, 2014 (Publications)
These guidelines harmonize many issues, but there are some discrepancies. METHODS: Leishmania parasites causing CL can now be genotyped by polymerase chain reaction techniques for detecting Leishmania
<em>In vitro</em> and <em>in vivo</em> activity of the chloroaryl-substituted imidazole viniconazole against <em>Trypanosoma cruzi</em> (Publications)
Chagas disease (CD) is caused by the intracellular protozoan parasite Trypanosoma cruzi and affects more than 10 million people in poor areas of Latin America. There is an urgent need for alternative drugs
Epidemiology of multiple<em> Plasmodium falciparum </em>infections. 4. Age dependence of the multiplicy of <em>Plasmodium falciparum</em> infections... (Publications)
the msp2 locus) occurred in 3-7 years old children. There was a significant correlation between parasite density and multiplicity of infection in infants and young children (1-2 years of age) but not in
Medicinal chemistry optimization of antiplasmodial imidazopyridazine hits from high throughput screening of a softfocus kinase library: part 2 (Publications)
antiplasmodial activity against NF54 (sensitive) and K1 (multidrug resistant) strains of the malaria parasite Plasmodium falciparum and evaluated for both aqueous solubility and metabolic stability. Selected
<em>In vitro</em> and<em> In vivo</em> evaluation of 28DAP010, a novel diamidine for treatment of second-stage African sleeping sickness (Publications)
e African sleeping sickness. The in vitro time to kill, determined by microcalorimetry, and the parasite clearance time in mice were shorter for 28DAP010 than for DB829. No cross-resistance was observed
Deorphaning pyrrolopyrazines as potent multi-target antimalarial agents (Publications)
resemblance between ligand binding sites in non-homologous target proteins, linking the observed parasite elimination to IspD, an enzyme from the non-mevalonate pathway of isoprenoid biosynthesis, and
Human African trypanosomiasis (Publications)
trypanosomiasis (sleeping sickness) occurs in sub-Saharan Africa. It is caused by the protozoan parasite Trypanosoma brucei, transmitted by tsetse flies. Almost all cases are due to Trypanosoma brucei
The spiroindolone drug candidate NITD609 potently inhibits gametocytogenesis and blocks <em>Plasmodium falciparum</em> transmission to Anopheles... (Publications)
entirely eradicating malaria. For that purpose, a key objective is blocking transmission of malaria parasites from humans to mosquito vectors. The new antimalarial drug candidate NITD609 was evaluated for its
Risk factors for epilepsy in rural Lao PDR: a case-control study (Publications)
first study in the Lao PDR on epilepsy risk factors representing important data for the subregion. Parasitic, environmental, and behavioral factors of this traditional population deserve further studies to
Antimalarial versus cytotoxic properties of dual drugs derived from 4-aminoquinolines and Mannich bases: interaction with DNA (Publications)
appropriate to be developed as antiproliferative agents against mammalian cancer cells than Plasmodium parasites